Charles River Laboratories has entered an agreement with German company Captain T Cell to focus on the production of plasmid DNA and retrovirus vectors for gene-modified cell therapy.

The collaboration is part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program, which provides Captain T Cell with access to contract development and manufacturing organisation (CDMO) expertise and advisory services.

The alliance is a strategic move for Captain T Cell as it prepares to manufacture a TCR-T cell therapy aimed at treating solid tumour patients in Phase I clinical trials.

Captain T Cell develops treatment options for solid tumours, aiming to extend the reach of T cell immunotherapies to new patient groups.

Its approach involves creating T cells equipped with tumour-specific T cell receptors (TCRs) with improved persistence and the ability to withstand the challenging tumour microenvironment of hard-to-treat solid tumours.

The T cells seek out and eliminate tumour cells, potentially offering a new therapeutic avenue for patients whose tumours are resistant to existing treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

To advance its gene-modified cell therapy to clinical stages, Captain T Cell will utilise the plasmid and viral vector production expertise of Charles River, which has been refined to aid CGT developers from pre-clinical through commercialisation.

Charles River has expanded its cell and gene therapy portfolio through acquisitions and facility expansions to streamline complex supply chains and cater to the increasing demand for plasmid DNA, viral vector and cell therapy services.

Charles River global manufacturing corporate senior vice-president Kerstin Dolph stated: “We are thrilled to work with the Captain T Cell team to support the manufacture of its TCR-T cell cancer immunotherapy.

“Charles River has decades of success reliably manufacturing plasmid DNA, viral vectors and cell therapies, helping to safeguard our customer programmes and bring potential therapies to patients with limited options.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.